BGMA Suggests Tweaks To UK Statutory Pricing Scheme Proposals

UK generics and biosimilars industry association the BGMA has published a formal response to a government consultation on the statutory scheme for branded medicine pricing, welcoming the recognition of the impact of competition in the government’s proposals but suggesting amendments to “minimize unintended consequences and align it to how the market operates.”